Kura Oncology’s (KURA) “Overweight” Rating Reiterated at Cantor Fitzgerald

Kura Oncology (NASDAQ:KURA)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research report issued on Wednesday,Benzinga reports.

A number of other research analysts have also issued reports on KURA. StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a report on Thursday, August 22nd. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Monday. HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of Kura Oncology in a research note on Wednesday. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Finally, UBS Group started coverage on Kura Oncology in a report on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.83.

Kura Oncology Stock Performance

NASDAQ KURA opened at $17.77 on Wednesday. The company has a fifty day moving average of $18.85 and a two-hundred day moving average of $19.99. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94. Kura Oncology has a 1 year low of $8.17 and a 1 year high of $24.17. The company has a market capitalization of $1.36 billion, a PE ratio of -7.97 and a beta of 0.86.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.53) EPS. As a group, analysts expect that Kura Oncology will post -2.46 earnings per share for the current year.

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. raised its stake in Kura Oncology by 12.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 40,970 shares of the company’s stock valued at $874,000 after purchasing an additional 4,659 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Kura Oncology in the first quarter valued at approximately $110,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Kura Oncology during the first quarter valued at approximately $507,000. ProShare Advisors LLC grew its stake in Kura Oncology by 9.7% in the 1st quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock worth $384,000 after acquiring an additional 1,588 shares during the period. Finally, Entropy Technologies LP acquired a new position in Kura Oncology in the 1st quarter valued at $218,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.